

EXPLANATION TO THE SUPPLEMENT II OF THE PROSPECTUS OF AESCAP GENETICS

This document contains an explanation regarding Supplement II to the Prospectus of Aescap Genetics dated December 2022 as amended from time to time (the “**Prospectus**”).

Supplement III to the Prospectus is also published on the website of the Fund Manager (the “**Supplement II**”).

The Prospectus of the Fund has been amended to make clear that if an Aescap fund managed by Privium Fund Management B.V. invests in Aescap Genetics, it will invest in the AESCAP GENETICS Manager Unit Class. As a result of which it is not charged with a management fee and performance fee.

As this Supplement II does not cause a reduction in Unit Holders’ rights or security, imposing costs on the Unit Holder or causing a change to the Investment Strategy, the change is effective immediately in accordance with section 22.4 of the Prospectus.

Amsterdam, 27 March 2024

Privium Fund Management B.V.

Fund Manager